# DESCRIPTION

## INTRODUCTION

- introduce protein translation
- describe error rates in translation
- introduce BMAA and its effects

## SUMMARY

- summarize L-serine's effect on BMAA incorporation
- describe Alzheimer's disease
- introduce L-serine as a drug candidate
- describe methods for preventing BMAA incorporation
- describe methods for preventing protein misfolding
- describe methods for treating neurological diseases
- introduce L-serine precursors, derivatives, and conjugates
- describe formulations and compositions
- introduce derivatives and isomers of BMAA
- describe neurological diseases and disorders
- describe symptoms of neurological diseases and disorders
- describe methods of administration
- describe dosages of L-serine

## DETAILED DESCRIPTION

- introduce BMAA and its effects on proteins
- describe L-serine as a treatment for neuronal disorders
- outline methods for preventing BMAA incorporation into proteins
- describe methods for preventing protein misfolding or aggregation
- outline methods for reducing risk of neurological diseases
- describe methods for stabilizing or reducing progression of neurological diseases
- outline methods for treating neurological diseases
- define neurological disorders and diseases
- describe therapeutic benefits of L-serine
- define therapeutic benefits and improvements
- describe successful treatment outcomes
- outline non-limiting symptoms of neurological disorders and diseases
- describe methods and uses for affecting underlying causes of diseases
- define sufficient or effective amounts of L-serine
- describe treatment outcomes and therapeutic effects
- outline satisfactory endpoints for treatment
- describe measurement of therapeutic benefits or treatment efficacy
- describe Alzheimer's disease diagnosis
- describe Amyotrophic Lateral Sclerosis diagnosis
- describe Parkinson's disease diagnosis
- describe Huntington's disease diagnosis
- describe Pick's disease diagnosis
- describe Frontotemporal dementia diagnosis
- define effective amount
- describe administration methods
- describe treatment timing
- describe composition administration
- define contacting
- define subject
- describe composition amounts
- introduce L-serine derivatives and conjugates
- describe hydroxyl protection groups
- describe amino protection groups
- describe acid protection groups
- describe derivatization of amino moiety
- describe derivatization of acid moiety
- describe L-serine conjugates with polymers
- describe starting materials for preparing L-serine derivatives and conjugates
- describe methods for synthesizing hydroxyl-protected serine compounds
- describe administration routes for L-serine and derivatives
- describe pharmaceutical formulations for L-serine and derivatives
- describe carriers and excipients for pharmaceutical formulations
- describe controlled release formulations
- describe biodegradable particles and polymeric substances
- describe microcapsules and colloidal dispersion systems
- describe additional pharmaceutical formulations
- describe kits for administering L-serine and derivatives
- describe instructions for using kits
- describe cell-free and cell-based methods for screening agents
- describe methods for identifying agents that modulate serine racemase activity
- describe methods for identifying agents that reduce incorporation of BMAA into proteins
- describe general definitions and terms used in the invention

### EXAMPLES

- describe materials and methods
- introduce cell culture
- study incorporation of BMAA into proteins
- examine inhibition of incorporation by cycloheximide and amino acids
- remove radiolabel from cell proteins
- recover incorporated BMAA from proteins following hydrolysis
- perform autofluorescence imaging of cells
- conduct lactate dehydrogenase assay
- perform acridine orange/ethidium bromide dual-staining of cells
- bind annexin V to phosphatidylserine exposed on the plasma membrane
- extract BMAA from fruit fly samples
- analyze BMAA in fruit fly samples using LC-MS/MS
- describe example 2
- show data indicating BMAA incorporation into proteins
- demonstrate inhibition of incorporation and misfolding/aggregation by L-serine
- describe BMAA incorporation into proteins
- illustrate apoptosis prevention by L-serine
- propose BMAA as a trigger for neurological disorders
- introduce Drosophila model for studying BMAA effects
- describe L-serine rescue of Drosophila from BMAA mortality
- introduce additional models for studying BMAA effects
- describe neurotoxicity of BMAA in zebrafish model
- illustrate abnormalities in neuronal development
- describe analysis of L-serine prevention of BMAA misincorporation
- introduce Vervet model for evaluating L-serine protective effect
- describe studies to evaluate Alzheimer's brains for BMAA-misincorporated proteins
- propose purification and analysis of proteins with BMAA misincorporation
- describe proposed human clinical trials of L-serine
- outline Phase I trial design for L-serine treatment of ALS
- describe inclusion and exclusion criteria for Phase I trial
- outline outcome measures for Phase I trial

